日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP)

在对度普利尤单抗治疗反应不足的成人和青少年中重度特应性皮炎患者中,从度普利尤单抗换用乌帕替尼:3b/4期研究(LEVEL UP)第2期疗效和安全性结果

Bunick, Christopher G; Magnolo, Nina; Moore, Angela; Abe, Masatoshi; Gao, Xinghua; Lynde, Charles; Ibrahim, Nadia; Levy, Gweneth; Calimlim, Brian M; Wu, Xiaoqiang; Armendariz, Yolanda; Grada, Ayman; Eyerich, Kilian

A Single-Cell and Spatial 3D Multi-omic Atlas of Developing Human Basal Ganglia and Inhibitory Neurons

人类基底神经节和抑制性神经元发育过程中的单细胞和空间三维多组学图谱

Heffel, Matthew G; Xu, Heng; Pastor-Alonso, Oier; Li, Xinzhe; Baig, Mohammad S; Irfan Ghoor, Rayyan; Li, Runjia; Kern, Colin; Kum, Joonho; Zhang, Yi; Paino, Jon; Tsai, Min Jen; Tai, Chu-Yi; Tucker, Grant; Zhao, Zoey; Hou, Angie; von Behren, Zachary; Bhade, Mohini; Li, Siqian; Sandoval, Kadellyn; Scholes, Jessica; Codrea, Felicia; Calimlim, Jeffrey; Liao, Emma K; Leung, Gwyneth; Kim, JaeYeon; Eskin, Eleazar; Flint, Jonathan; Cotter, Jennifer A; Pasaniuc, Bogdan; Bintu, Bogdan; Zhu, Quan; Mukamel, Eran A; Ernst, Jason; Paredes, Mercedes F; Luo, Chongyuan

Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks

Upadacitinib治疗中重度特应性皮炎患者的疗效和安全性:3期随机临床试验140周结果

Irvine, Alan D; Prajapati, Vimal H; Guttman-Yassky, Emma; Simpson, Eric L; Papp, Kim A; Blauvelt, Andrew; Chu, Chia-Yu; Hong, H Chih-Ho; Gold, Linda F Stein; de Bruin-Weller, Marjolein; Bieber, Thomas; Kabashima, Kenji; Rosmarin, David; Sancho, Cristina; Calimlim, Brian M; Grada, Ayman; Yang, Yang; Wu, Xiaoqiang; Levy, Gweneth; Raymundo, Eliza M; Teixeira, Henrique D; Silverberg, Jonathan I

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis

Upadacitinib 与安慰剂(Measure Up 1 和 Measure Up 2)以及与 Dupilumab(Heads Up)相比,能快速改善瘙痒和清除皮肤:三项针对中重度特应性皮炎患者的 3 期临床试验结果

Simpson, Eric L; Silverberg, Jonathan I; Prajapati, Vimal H; Eyerich, Kilian; Katoh, Norito; Boguniewicz, Mark; Guttman-Yassky, Emma; Song, E James; Lee, Wan-Ju; Teixeira, Henrique D; Wu, Tianshuang; Sancho Sanchez, Cristina; Vigna, Namita; Calimlim, Brian M; de Bruin-Weller, Marjolein

Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

使用 Upadacitinib 治疗中重度特应性皮炎,实现最佳治疗目标和最小疾病活动度:3 期研究(Measure Up 1 和 2)的综合分析

Silverberg, Jonathan I; Gooderham, Melinda; Katoh, Norito; Aoki, Valeria; Pink, Andrew E; Binamer, Yousef; Glick, Brad; Staubach, Petra; Calimlim, Brian; Li, Chao; Grada, Ayman; Moreira, Alvaro; Lee, Wan-Ju; Wollenberg, Andreas

Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis

达到最佳治疗目标和最小疾病活动度对特应性皮炎患者健康相关生活质量和满意度的影响

Silverberg, Jonathan I; Gooderham, Melinda; Wollenberg, Andreas; Pink, Andrew E; Ruiz Dasilva, Diego; Kwatra, Shawn G; Binamer, Yousef; Katoh, Norito; Aoki, Valeria; Moreira, Alvaro; Grada, Ayman; Li, Chao; Calimlim, Brian; Lee, Wan-Ju; Bunick, Christopher G

Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study

乌帕替尼与度普利尤单抗治疗中重度特应性皮炎在四个身体区域的疗效和安全性比较:来自 HEAD UP 研究的分析

Thyssen, Jacob P; Rosmarin, David; Costanzo, Antonio; Warren, Richard; Chu, Chia-Yu; Chovatiya, Raj; Ladizinski, Barry; Hu, Xiaofei; Liu, Yingyi; Calimlim, Brian; Nduaka, Chudi; Vigna, Namita; Armstrong, April

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks

乌帕替尼治疗中重度特应性皮炎青少年:3项3期随机临床试验76周分析

Paller, Amy S; Mendes-Bastos, Pedro; Siegfried, Elaine; Eichenfield, Lawrence F; Soong, Weily; Prajapati, Vimal H; Lio, Peter; Simpson, Eric L; Raymundo, Eliza M; Suravaram, Smitha; Hu, Xiaofei; Yang, Yang; Huang, Xiaohong; Calimlim, Brian M; Platt, Andrew M; Su, John C; Zheng, Min; Yamamoto-Hanada, Kiwako; Teixeira, Henrique D; Irvine, Alan D

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)

Upadacitinib 可早期且持续改善中重度特应性皮炎成人和青少年患者的症状和生活质量:两项 III 期随机临床试验(Measure Up 1 和 Measure Up 2)的 52 周结果

Silverberg, Jonathan I; Gooderham, Melinda J; Paller, Amy S; Deleuran, Mette; Bunick, Christopher G; Gold, Linda F Stein; Hijnen, DirkJan; Calimlim, Brian M; Lee, Wan-Ju; Teixeira, Henrique D; Hu, Xiaofei; Zhang, Shiyu; Yang, Yang; Grada, Ayman; Platt, Andrew M; Thaçi, Diamant

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis

乌帕替尼和度普利尤单抗在实现严格的综合皮肤和瘙痒结局方面的疗效:中重度特应性皮炎成人患者的间接比较

Armstrong, April W; Hong, H Chih-Ho; Calimlim, Brian M; Buessing, Marric G; Crowell, Marjorie M; Silverberg, Jonathan I